ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
MediWound Announces NexoBrid BLA Acceptance for Severe Thermal Burns
September 23, 2020MediWound announced the U.S. Food and Drug Administration (FDA) has accepted for review its recently submitted Biologics License Application (BLA) for NexoBrid® for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness.. -
MediWound Submits BLA Severe Thermal Burn Treatment
July 10, 2020MediWound has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking the approval of NexoBrid® for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.
Pharma Sources Insight January 2025
